Evidence map›Paper›PMID 25526734›Full record

ArticleNeuro-oncology2015

Imaging of gliomas at 1.5 and 3 Tesla - A comparative study.

Lambros Tselikas, Raphaëlle Souillard-Scemama, Olivier Naggara, Charles Mellerio, Pascale Varlet, Edouard Dezamis, Julien Domont, Frédéric Dhermain, Bertrand Devaux, Fabrice Chrétien and 3 more

Abstract readComparative Study

PubMed Full text at PMC Publisher

In one paragraph

Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it

0cells of the map it votes in

14citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.European radiology · 2016
Trial
Improved detection of brain metastases using contrast-enhanced 3D black-blood TSE sequences compared to post-contrast 3D T1 GRE: a comparative study on 1.5-T MRI.European radiology · 2025
Article
How to evaluate perfusion imaging in post-treatment glioma: a comparison of three different analysis methods.Neuroradiology · 2024
Article
Ventricular entry during surgical resection is associated with intracranial leptomeningeal dissemination in glioblastoma patients.Journal of neuro-oncology · 2022
Article
The Promise of Magnetic Resonance Imaging in Radiation Oncology Practice in the Management of Brain, Prostate, and GI Malignancies.JCO global oncology · 2022
Review
Intraoperative 3 T MRI is more correlative to residual disease extent than early postoperative MRI.Journal of neuro-oncology · 2021
Article
Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics.Scientific reports · 2020
Article
Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.Neuro-oncology · 2020
Article
Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma.Frontiers in neurology · 2020
Article
A feasibility study to evaluate early treatment response of brain metastases one week after stereotactic radiosurgery using perfusion weighted imaging.PloS one · 2020
Article
Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.Journal of neuro-oncology · 2017
Article
Intra-rater variability in low-grade glioma segmentation.Journal of neuro-oncology · 2017
Article
Detection superiority of 7 T MRI protocol in patients with epilepsy and suspected focal cortical dysplasia.Acta neurologica Belgica · 2016
Article
A novel vascular model yields increased MR perfusion metrics compared to conventional dynamic susceptibility contrast algorithms in untreated glioblastoma.Neuro-oncology advances
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lambros TselikasNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Raphaëlle Souillard-ScemamaNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Olivier NaggaraNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Charles MellerioNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Pascale VarletNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Edouard DezamisNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Julien DomontNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Frédéric DhermainNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Bertrand DevauxNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Fabrice ChrétienNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Jean-François MederNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Johan PalludNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Catherine OppenheimNeuroimaging Department, Centre Hospitalier Sainte-Anne, Paris, France (L.T., R.S.-S., O.N., C.M., J.-F.M., C.O.); Neurosurgery Department, Centre Hospitalier Sainte-Anne, Paris, France (E.D., B.D., J.P.); Neuropathology Department, Centre Hospitalier Sainte-Anne, Paris, France (P.V., F.C.); INSERM U 894 Centre Hospitalier Sainte-Anne, Paris, France (O.N., C.O.); Radiation Therapy and Physics Department, Gustave Roussy Institute, Villejuif, France (F.D.); Medical Oncology department, Gustave Roussy Institute, Villejuif, France (J.D.); Université Paris Descartes, Paris, France (O.N., P.V., F.C., J.-F.M., J.P., C.O.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioma follow-up is based on MRI parameters, which are correlated with survival. Although established criteria are used to evaluate tumor response, radiological markers may be confounded by differences in instrumentation including the magnetic field strength. We assessed whether MRIs obtained at 3 Tesla (T) and 1.5T provided similar information.

methodsWe retrospectively compared imaging features of 30 consecutive patients with WHO grades II and III gliomas who underwent MRI at 1.5T and 3T within a month of each other, without any clinical changes during the same period. We compared lesion volumes on fluid attenuation inversion recovery (FLAIR), ratio of cerebral blood volume (rCBV) on perfusion-weighted imaging, contrast-to-noise ratio (CNR) on FLAIR, and on post-gadolinium 3D T1-weighted sequences between 1.5T and 3T using intraclass correlation coefficient (ICC). Concordance between observers within and between modalities was evaluated using weighted-kappa coefficient (wκ).

resultsThe mean ± SD delay between modalities (1.5T and 3T MRI) was 8.6 ± 5.6 days. Interobserver/intraobserver concordance for lesion volume was almost perfect for 1.5T (ICC = 0.96/0.97) and 3T (ICC = 0.99/0.98). Agreement between observers for contrast enhancement was excellent at 1.5T (wκ = 0.92) and 3T (wκ = 0.92). The tumor CNR was significantly higher for FLAIR at 1.5T (P < .001), but it was higher at 3T (P = .012) for contrast enhancement. Correlations between modalities for lesion volume (ICC = 0.97) and for rCBV values (ICC = 0.92) were almost perfect.

conclusionsIn the follow-up of WHO grades II and III gliomas, 1.5T and 3T provide similar MRI features, suggesting that monitoring could be performed on either a 1.5 or a 3T MR magnet.

Indexed as

Contrast MediaDiagnosis, Computer-AssistedFemaleGadoliniumGliomaHumansMagnetic FieldsMagnetic Resonance ImagingMaleMiddle AgedObserver VariationRadionuclide ImagingReproducibility of ResultsRetrospective StudiesSupratentorial NeoplasmsContrast MediaGadoliniumgliomaMRIneuroimagingobserver variationreproducibility of results

Identifiers

PMID25526734

DOI10.1093/neuonc/nou332

PMCPMC4483120

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.